The chemotheraputic agent cisplatin is commonly used to treat OSA in both species and significantly upregulates NQO1 in cancer cells, increasing their sensitivity to β-lapachone in vitro and in vivo [65]. This evidence concerns the gene NQO1 and obstructive sleep apnea syndrome.